Go to the list of all blogs
Allana's Avatar
published in Blogs
May 17, 2019
TickeronGET DAILY SIGNALS
Five states to join lawsuit of OxyContin maker Purdue Pharma

Five states to join lawsuit of OxyContin maker Purdue Pharma

Five U.S. states filed lawsuits accusing Purdue Pharma of illegally marketing and selling opioids, escalating the wave of litigation over a nationwide abuse epidemic. Iowa, Kansas, Maryland, West Virginia and Wisconsin joined 39 states to file lawsuits targeting Purdue Pharma and its leaders, including former president Richard Sackler and his family. 

Officials accused Purdue Pharma of repeatedly making false and deceptive claims that opioids, including OxyContin, were safe for a wide range of patients seeking to reduce pain. 

Purdue Pharma called the new lawsuits “misleading attacks.” “These complaints are part of a continuing effort to try these cases in the court of public opinion rather than the justice system,” the Stamford, Connecticut-based company said.

Related Ticker: FTXH

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


FTXH in downward trend: price dove below 50-day moving average on November 19, 2026

FTXH moved below its 50-day moving average on November 19, 2026 date and that indicates a change from an upward trend to a downward trend. In 35 of 44 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 80%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for FTXH moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In 26 of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at 79%.

The Momentum Indicator moved below the 0 level on November 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FTXH as a result. In 62 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 72%.

The Moving Average Convergence Divergence Histogram (MACD) for FTXH turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 34 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 68%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FTXH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The 10-day moving average for FTXH crossed bullishly above the 50-day moving average on October 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.

Following a +2.87% 3-day Advance, the price is estimated to grow further. Considering data from situations where FTXH advanced for three days, in 252 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

FTXH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 219 of 278 cases where FTXH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN).

Industry description

The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of the Nasdaq U.S. Smart Pharmaceuticals TM Index. The fund will normally invest at least 80% of its net assets (including investment borrowings) in the securities that comprise the index. The index is designed to provide exposure to U.S. companies comprising the pharmaceutical sector that have been selected based upon their liquidity and ranking. It is non-diversified.

Market Cap

The average market capitalization across the First Trust Nasdaq Pharmaceuticals ETF (FTXH) ETF is 77.04B. The market cap for tickers in the group ranges from 3.62B to 1.21T. LLY holds the highest valuation in this group at 1.21T. The lowest valued company is ELVN at 3.62B.

High and low price notable news

The average weekly price growth across all stocks in the First Trust Nasdaq Pharmaceuticals ETF (FTXH) ETF was -6%. For the same ETF, the average monthly price growth was -2%, and the average quarterly price growth was 20%. BMRN experienced the highest price growth at 6%, while CAI experienced the biggest fall at -24%.

Volume

The average weekly volume growth across all stocks in the First Trust Nasdaq Pharmaceuticals ETF (FTXH) ETF was 53%. For the same stocks of the ETF, the average monthly volume growth was 35% and the average quarterly volume growth was 15%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 61
P/E Growth Rating: 52
Price Growth Rating: 45
SMR Rating: 67
Profit Risk Rating: 56
Seasonality Score: 18 (-100 ... +100)
AI Screener 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
Interact to see
Advertisement
SSO is a 2x daily leveraged ETF (exchange-traded fund) that seeks double the daily return of the S&P 500, while XXX is a non-leveraged, passive fund blending roughly 75% S&P 500 exposure with 25% XRP, a major cryptocurrency. Both funds charge comparable fees — about 0.87% for SSO and roughly 0.85% for XXX — but their risk profiles are fundamentally different.
Alphabet Inc. (GOOG) , the parent of Google, YouTube, and Google Cloud, is a common stock, not an exchange-traded fund. The central target of $400 is the arithmetic mean of current analyst price targets, which span a wide band from roughly $300 to $500, with the broad average near $397.
AAPL has shown stronger relative performance in recent weeks, holding near record highs while many artificial intelligence (AI)-focused tech stocks sold off. MSFT has lagged the market and now trades below its 50-day moving average amid concerns over heavy AI infrastructure spending.
Bending Spoons reported third-quarter 2026 revenue of $780.22 million, up 125.1% year over year and above the roughly $745.86 million consensus estimate. Earnings per share (EPS) came in at $0.42, beating the $0.26 consensus estimate by $0.16.
GOOG declined roughly 20% over the past 30 days, falling from about $331 to around $264 per share. The sell-off was triggered by Alphabet's third-quarter 2026 report, which revealed slowing Search advertising growth and an earnings miss.